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Abstract: Water contamination by cyanobacterial blooms is a worldwide health hazard to humans as
well as livestock. Exposure to Microcystins (MCs), toxins produced by various cyanobacterial or blue
green algae found in poorly treated drinking water or contaminated seafood such as fish or prawns are
associated with hepatotoxicity, nephropathy and neurotoxicity and in extreme cases, death in humans.
MC congeners, currently >240 known, differ dramatically in their uptake kinetics, i.e. their uptake via
OATP1B1 and OATP1B3, in OATP overexpressing human HEK293 cells and primary human hepato-
cytes. It is thus likely that MC congeners will also differ with respect to the cellular efflux of the parent
and conjugated congeners, e.g. via MRPs, MDRs, BCRP or BSEP. Consequently, the role and kinetics
of different human efflux transporters - MRP, MDR, BCRP and BSEP in MC efflux was studied using
insect membrane vesicles overexpressing the human transporters of interest. Of the efflux transporters
investigated, MRP2 displayed MC transport. Michaelis-Menten kinetics displayed mild co-operativity
and thus allosteric behavior of MRP2. MC transport by MRP2 was MC congener-specific, whereby
MC-LF was transported more rapidly than MC-LR and -RR. Other human transporters (BCRP, BSEP,
MRP1,3,5, MDR1) tested in this study did not exhibit interaction with MC. Although MRP2 showed
specific MC transport, the MC-LR-GSH conjugate, was not transported suggesting the involvement of
other transporters than MRP2 for the conjugate efflux.
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15  Human efflux transporters were tested for microcystin (MC) transport
16  MC transport was verified via UPLC-MS/MS analyses
17  Of the human efflux transporters only human MRP2 demonstrated MC transport 
18  MRP2 mediated MC transport was MC-congener dependent, whereby MC-LF>MC-LR>MC-RR
19  No MRP2 mediated transport could be observed for the MC-glutathione conjugate
20 Abstract: Water contamination by cyanobacterial blooms is a worldwide health hazard to humans as well as 
21 livestock. Exposure to Microcystins (MCs), toxins produced by various cyanobacterial or blue green algae 
22 found in poorly treated drinking water or contaminated seafood such as fish or prawns are associated with 
23 hepatotoxicity, nephropathy and neurotoxicity and in extreme cases, death in humans. MC congeners, currently 
24 >240 known, differ dramatically in their uptake kinetics, i.e. their uptake via OATP1B1 and OATP1B3, in 
25 OATP overexpressing human HEK293 cells and primary human hepatocytes. It is thus likely that MC congeners 
26 will also differ with respect to the cellular efflux of the parent and conjugated congeners, e.g. via MRPs, MDRs, 
27 BCRP or BSEP. Consequently, the role and kinetics of different human efflux transporters - MRP, MDR, BCRP 
28 and BSEP in MC efflux was studied using insect membrane vesicles overexpressing transporters of interest. Of 
29 the efflux transporters investigated, MRP2 displayed MC transport. Michaelis-Menten kinetics displayed mild 
30 co-operativity and thus allosteric behavior of MRP2. MC transport by MRP2 was MC congener-specific, 
31 whereby MC-LF was transported more rapidly than MC-LR and -RR. Other human transporters (BCRP, BSEP, 
32 MRP1,3,5, MDR1) tested in this study did not exhibit interaction with MC. Although MRP2 showed specific 
33 MC transport, the MC-LR-GSH conjugate, was not transported suggesting the presence of additional 
34 mechanism(s) for the conjugate efflux. 
35 Keywords: human MRP2; microcystin; human efflux transporters 
36 Key Contribution: We have shown that only MRP2 transports MC among the tested human efflux transporters 
37 (BCRP, BSEP, MRP1,2,3,5, and MDR1) in insect cell membrane vesicles. 
38
39 Introduction
40 Water contamination by cyanobacterial blooms and the associated toxins, e.g. the microcystins (MCs) is 
41 a worldwide health hazard to humans. The bloom that affected almost 1000 km of the Barwon-Darling River, 
42 New South Wales, Australia, in November and December 1991 [1], the deaths of renal dialysis patients in 1996 
43 in Caruaru, Brazil [2], or the most recent closing of the drinking water supply for the inhabitants of Toledo, 
44 Ohio, USA, resulting from recurrent Microcystis aeruginosa blooms in Lake Erie [3], are just a few of the many 
45 prominent examples. Exposure of humans to MC, of which more than 240 different congeners are known to 
46 date [4], have been shown to be causal in the development of hepatotoxicity and neurotoxicity and death [2]. 
47 The latter has been corroborated via a plethora of in vitro experiments with primary human or rodent cells [5-
48 7] and in vivo exposures of rodents [8-10]. 
Cellular uptake of MC specifically occurs via organic anion polypeptide transporters (OATPs) [11] in 
humans, rodents and fish [5-7, 12, 13]. Once within the cell, MCs specifically interact with Ser/Thr protein 
phosphatases (PPPs) [14] as well as with other thiol containing proteins and peptides e.g. glutathione [15]. 
While the reversible and subsequently covalent binding to and thus inhibition of Ser/Thr protein phosphatases 
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[14, 16] is established to be the principle underlying mechanism of the observed cytotoxicity, the mechanisms 
and transporters involved in the excretion of MCs from the cells is less well understood. Indeed, despite that 
glutathione-conjugation of MCs was demonstrated [15, 17, 18] and the presence of MCs in the bile of trout was 
confirmed [19], it remains to be mechanistically proven whether unbound MC and/or conjugated MC is excreted 
into the bile by a given exporter. A recent report suggested that zebrafish Abcb4, with high sequence and 
functional homology to mammalian ABCB1 (multi-drug resistance protein 1, MDR1), is involved in the biliary 
excretion of MC-LR [20]. However, questions as to the specific uptake of MC-LR in the zebrafish embryos and 
in Abcb4-overexpressing LLC-PK1 cells, which do not express OATP [21], as well as with regard to the 
detection of intra-embryonic and intra-cellular bound and free MC-LR, limit the confidence as to Abcb4 
involvement in MC-LR excretion.
49 Figure 1. Human hepatocyte influx and efflux transporters. Known efflux transporters important for 
50 excretion/elimination of xenobiotics and drugs into bile at canalicular membrane and/or back into blood at 
51 sinusoidal membrane are shown. The human transporters: BCRP, BSEP, MRP1,2,3, and MDR1 were used in 
52 the membrane vesicle study (in blue). MRP5 was also tested albeit it is not expressed in hepatocytes. The 
53 location of MC importing transporters, OATP1B1 and OATP1B3 on the sinusoidal membrane is also indicated. 
54 Adapted from [22].
55 In order to provide better insight into the involvement of known human efflux transporters (Figure 1) in 
56 the excretion of unbound or conjugated MCs, we investigated the role and kinetics of different efflux 
57 transporters - MDR, MRPs, BCRP and BSEP in MC secretion using insect cell membrane vesicles specifically 
58 overexpressing ABC-transporters. Moreover, as our earlier data [5-7] strongly suggest that transport is MC 
59 congener dependent, we employed three different MC congeners (MC-LR, -LF and -RR) for the transport 
60 assays. Our present data suggest a specific role for MRP2 in transporting MCs while the other efflux transporters 
61 did not show transport of free MCs under the conditions tested. MRP2 MC efflux kinetics was congener 
62 specific, whereby MC-LF was transported at higher capacity than MC-LR or -RR.
63 Materials and Methods 
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64 Materials: Microcystin congeners (MC-LR, MC-LR, MC-RR) were purchased from Enzo life sciences, 
65 Loerrach, Germany. PREDIVEZTM vesicular transport assay kits 
66 (https://www.solvobiotech.com/products/categories/predivez-vesicular-transport-reagent-kits) for human 
67 transporters, BCRP, MRP1,2,3,5 and MDR1, and membrane vesicles for BSEP (hBSEP-HEK293-VT) were 
68 procured from Solvo Biotech, Budapest, Hungary under the ReACTs program (details in Table 1). Radioactive 
69 substrates, tritium labeled N-methyl-quinidinium chloride or 3H-NMQ (for MDR1) and tritium labeled 
70 taurocholic acid or taurine-2-3H (for BSEP) were purchased from Biotrend, Cologne, Germany and American 
71 radiolabeled chemicals, St. Louis, USA respectively. Dimethyl sulfoxide (DMSO) (>99.98 %) was purchased 
72 from Roth. Methanol (99.8%), LC-MS grade formic acid and ammonium hydroxide were purchased from 
73 Sigma-Aldrich. All solvents for mass spectrometry were of LC-MS grade from Roth, Germany.
74 Vesicular transport assay: all microcystin congeners were dissolved in methanol (final solvent 
75 concentration 1%) while all inhibitors were dissolved in DMSO (final solvent concentration 1%). For the efflux 
76 transporters- BCRP, MRP1,2,3,5 and MDR1, the assay was performed essentially as given in the PREDIVEZTM 
77 kit. The assay protocol determined the interaction of MC with the specific transporter in insect membrane vesicles 
78 using the modulation of transport of a known fluorescent/radioactive substrate. Briefly, various concentrations of 
79 MC-LR (0.41-300 µM for BCRP, MRP1,3,5 and MDR1; 0.41-1.8 mM for MRP2) or inhibitor (benzbromarone: 
80 0.21-300 µM, omeprazole: 0.41-300 µM and verapamil: 0.41-300 µM) or solvent control (methanol or DMSO) 
81 were added to the membrane vesicle suspension (50 µg/well) in presence of AMP (12 mM) or ATP (12 mM) in 
82 75 µl assay buffer (PREDIVEZTM kit). For comparison of MRP2 mediated MC-LF, MC-LR and MC-RR transport, 
83 equal concentrations of MC congeners (33.3 µM) were added. The samples were incubated at 37 °C for 3-30 min 
84 (dependent on the assay, Table 1). After the reaction was completed, the membrane vesicles were collected on 
85 Millipore filter plates under vacuum and washed three times with 200 µl 1X wash buffer (PREDIVEZTM kit). After 
86 solubilization in 100 µl detector solution (10 min, RT), the accumulated fluorescence or radioactivity was 
87 measured on a Tecan reader or scintillation counter (after adding 500 µl scintillation liquid) respectively. 
88 For BSEP, the assay was performed as given in (Marroquin et al., 2017) with minor modifications. Briefly, 
89 various concentrations (0.41-300 µM) of MC-LR or inhibitor (glyburide: 0.013-200 µM) or solvent control 
90 (methanol or DMSO) were added to hBSEP vesicle suspension (50 µg/well) in taurine-2-H3 (15,000 dpm/pmol) 
91 containing assay buffer (50 mM HEPES, pH 7.5, 100 mM KNO3,10 mM Mg(NO3)2, 50 mM sucrose, 2 μM 
92 taurocholic acid/ [taurine -2-3H], 5 % DMSO) in presence of AMP (4 mM) or ATP (4 mM) and incubated for 
93 40 min at room temperature on a shaker. Once the transport was complete, the samples were washed with 200 µl 
94 assay buffer (without radioactive substrate) and collected on Millipore 96-well filter plates and dried under 
95 vacuum. Dried vesicle samples were dissolved using 100 µl 1X detector solution (from MRP5 PREDIVEZTM Kit) 
96 for complete dissolution of vesicles and suspended in 500 µl of scintillation liquid. Total radioactivity/well (dpm) 
97 was measured to calculate the competitive transport in presence of MC-LR.  
98 Relative % transport in the inhibition experiments was calculated using vehicle control (methanol or DMSO) 
99 as 100% transport. Control membrane vesicles from the same source but lacking the transporter were used as 
100 confirmation of no transport in the absence of transporter. Inhibitors for fluorescent/radioactive substrate transport 
101 were used to confirm the functionality of the assays. Experimental data were evaluated by nonlinear regression 
102 analysis using GraphPad Prism 5 Software (San Diego, CA). Table 1 summarizes assay details for each transporter 
103 used in this study.  
104 Table 1. Assay details of each tested transporter using the insect membrane vesicle approach. Probe 
105 substrate, inhibitor with incubation times are mentioned for each human transporter. Control membrane vesicles 
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108 LC-MS/MS MC-LR detection: To determine MC-LR transport in MRP2 membrane vesicles, once the 
109 vesicular transport was complete and vesicles were collected on filter after washing (see above), 100 µl ice cold 
110 MeOH:H2O (2:1) was added to the vesicle samples and incubated for 10 minutes at 2-8 °C. After vacuum filtration, 
111 these samples were collected and subjected to UPLC-MS/MS (Waters, Eschborn, Germany) to determine the 
112 accumulated MC-LR in each sample using an already developed method described in Altaner et al. [42]. Briefly, 
113 analysis of samples was performed on an ACQUITY UPLC H-class coupled to a Xevo TQ-S tandem MS (Waters). 
114 The UPLC equipped with a Waters Acquity BEH C18 column (1.6 µm, 2.1 × 50 mm) at a flow rate of 0.4 ml/min 
115 was used for detection of a 135 m/z daughter ion, representative of microcystin fragmentation with an LOD of 2 
116 nM and an LOQ of 3-5 nM. Mobile phases A: 10% acetonitrile and B: 90% acetonitrile, both supplemented with 
117 100mM formic acid and 6 mM ammonia were used. Column temperature was set to 40 °C and the injected 
118 sample volume was 5 µl. The following gradient with a total runtime of 7 min was used: the sample was loaded 
119 in 75% A, 25% B and gradient increased to 1% A, 99% B in initial 4.2 min and held for 0.5 min; the solvent 
120 composition was returned to 75% A, 25% B at 6 min and the column re-equilibrated for 1 min. Compounds 
121 entering the mass spectrometer were ionized using a capillary voltage of 3 kV, cone gas flow of 150 l/h and a 
122 nebulizer pressure of 7.0 bar. For dissolution, a nitrogen flow of 1000 l/h at 500 °C was used. Once the MC-LR 
123 levels (ng/ml) were obtained using TargetLynx software (Waters), kinetic parameters by fitting calculated MC-
124 LR transport values (nmol/mg/min) to the Michaelis–Menten equation by nonlinear regression analysis were 
125 generated. The data was further transformed for analysis with the Hanes–Woolf plots using Graph Pad Prism 5. 
126 MC-LR-GSH synthesis: Semi-preparative HPLC was performed with a LC-20A prominence system by 
127 Shimadzu (degasser: DGU-20A3, pumps: LC-20AT, autosampler: SIL-20A, communication module: CBM-20A, 
128 diode array detector: SPD-M20A (D2 lamp), column oven: CTO-20AC) with a Vydac® Protein and Peptide C18 
129 4.6 x 250 mm, 5 µM column by Grace (flow rate 0.9 ml/min). Analytical LC-MS was performed with a 
130 LCMS2020 by Shimadzu (pumps: LC-20 AD, auto sampler: SIL-20A HT, UV-Vis detector: SPD-20A, oven: 
131 CTO-20AC, communications bus module: CBM-20A, ESI detector, software LCMS-Solution) with a Kinetex® 
132 2.6 µM C18 100 Å, 150 x 4.6 mm column by phenomenex (flow rate 0.4 ml/min). For both LC devices a binary 
133 gradient of acetonitrile (Solvent B) in water (Solvent A) supplemented with 0.1% formic acid was used. High 
134 resolution mass spectrometry (HRMS) was measured on a micrOTOF II from Bruker and analyzed with Xcalibur 
135 v3.0 by Thermo Fischer Scientific.
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136 MC-LR (0.5 mg, 0.5 µmol) was dissolved in methanol (200 µl) and glutathione (7.4 mg, 24.1 µmol) in water 
137 (210 µl) was added. After addition of 1 M KOH (42 µl), the reaction mixture was incubated at 40 °C for 1 h under 
138 gentle mixing. The crude product was purified by HPLC (gradient: 30-100% B in 15 min) and the MC-LR-GSH 
139 adduct (Rt= 10.0 min, 350 µg, 0.27 µmol, 54%) was obtained as a white solid. LC-MS analysis (gradient: 30-75% 
140 B in 15 min) of the purified product (Rt= 7.2 min) gave a single peak with the correct mass (Suppl. Fig 2). HRMS 
141 m/z calculated for C59H93N13O18S2+: 651.8236 [M+2H+]; found: 651.8237.
142 Data analysis: For all figures, mean ± SEM is shown for at least 3 true replicates unless otherwise specified. 
143 For statistical analysis of Figure 4, ANOVA with Bonferroni correction and an additional t-test was used for 
144 pairwise comparisons.
145 Results
146 We [19] and others [23-25] have reported the presence of unconjugated MCs in bile and urine respectively 
147 of trout, carp and pig. To establish which efflux transporter could be involved in a possible biliary secretion of 
148 MCs in humans, we utilized insect cell vesicles over-expressing eight human ABC-transporters to assess 
149 possible transport of MCs. These membrane vesicles consisted of total cell membrane fractions forming vesicles 
150 but lacking, nucleosolic and cytosolic components. As the orientation of the vesicles is random, part of the 
151 efflux transporters of interest are present in an inside-out configuration. The consequence of the latter is the 
152 inversion of the original direction of transport of the efflux transporter and absence of intracellular components 
153 potentially interacting with the transported substrate of interest and thus resulting in the accumulation of a 
154 known transporter substrate in the lumen (inside) of the membrane vesicle. Interaction with the transporter 
155 could then be quantified using either fluorescent or radioactive labelled standard substrates. Thus, if a given 
156 MC congener is a substrate of a specific ABC-transporter it should compete with its fluorescent or radioactively 
157 labelled substrate thereby reducing the rate of the labelled substrate transport and intra vesicular lumen 
158 accumulation. 
159 Based on our previous study [19] in trout, a specific transport mechanism for excretion into bile was suggested, 
160 we thus tested whether a priori MRP2, localized at the bile canalicular membrane (Figure 1) is involved in MC 
161 efflux, albeit knowing that other transporters e.g. MDR1 could be responsible as well [26]. For this purpose, 
162 we incubated MRP2 insect membrane vesicles in the presence of the prototypical MRP2 substrate CDCF with 
163 increasing MC-LR concentrations in presence of ATP or AMP. Obviously with this type of experimental set-
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164 up we cannot make any inference on the type of transport inhibition, i.e. whether this results from mere binding 
165 to the transporter or resulted from competitive interaction at the substrate binding site. As expected, a decreased 
166 CDCF transport was observed with increasing MC-LR concentration (Figure 2A). Decreased CDCF 
167 accumulation in MRP2 membrane vesicles was also observed with increasing concentrations of benzbromarone 
168 (Figure 2B), an inhibitor of MRP2 [27] (Table 1). In contrast, in the absence of MRP2 expression, no CDCF 
169 transport was observed irrespective of whether or not MC-LR and benzbromarone were present (Figure 2C-D). 
170 The latter data confirmed the functionality of the MRP2 expressed in the membrane vesicles, excluded passive 
171 entry of CDCF by diffusion into the vesicular lumen and make an unspecific membrane alteration by MC-LR 
172 very unlikely. Moreover, these data demonstrated MC-LR concentration-dependent modulation of CDCF 
173 transport, thereby corroborating the initial assumption that MC-LR, de minimis, binds to MRP2. 
174 Figure 2. MRP2-mediated CDCF transport in the presence of MC-LR in insect membrane vesicles. A. In 
175 an indirect vesicular transport assay approach, decrease in CDCF fluorescence was observed with increasing 
176 MC-LR concentration in MRP2- membrane vesicle fractions. B. The MRP2 inhibiting benzbromarone [27] was 
177 used as a control to demonstrate CDCF transport inhibition. Membrane vesicle samples without transporters 
178 were used as negative control for MC-LR (C) and benzbromarone transport (D). The absolute Relative 
179 Fluorescence Units (RFU) for 100% CDCF transport were 36701 ± 2852. Shown are n= 3 true replicates, mean 
180 ± SEM. 
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181  
182 Figure 3. LC-MS/MS detection of MC-LR uptake in MRP2-membrane vesicles and assessment of 
183 Michaelis-Menten kinetics. Vesicular lumen content of MRP2-membrane vesicles treated with different 
184 concentrations of MC-LR were subjected to LC-MS/MS analysis. A: representative LC-MS/MS full scan of 
185 MC-LR (M+H+=995) with daughter ion at 135 m/z, used for detection. B. Michaelis-Menten kinetics of MC-
186 LR concentrations within the vesicular lumen, transformed to a Hanes-Woolf plot (inset), displaying mild 
187 cooperativity (arrow). Shown are n= 3 true replicates; mean ± SEM.
188 To confirm that MC-LR is actually transported by MRP2, the MC-LR lumen concentration of MRP2 
189 membrane vesicles exposed to increasing MC-LR concentrations were analyzed using LC-MS/MS (Figure 3A) 
190 and the analytical data evaluated using Michaelis-Menten kinetics (Figure 3B). The rate of MC-LR transport 
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191 increased with MC-LR concentrations. Vmax was approximated to 235 nmol MC-LR /mg prot x min. 
192 Transformation of the data using a Hanes-Woolf plot (Figure 3B inset) suggested mild cooperativity [28] and 
193 thus an allosteric behavior of MRP2, as was also shown previously for other low-molecular weight MRP2 
194 substrates [29]. This precludes an exact calculation of the km value. It has previously been postulated [30, 31] 
195 that the binding site of MRP2 may be rather large and in case of small substrates, two substrate molecules (here, 
196 MC-LR) may bind sequentially to or close to the binding site, leading to an allosteric behavior of MRP2, visible 
197 as the curvature (marked by the arrow) on the plot.
198 To assess whether MC congener structure variability has an impact on MRP2 transport, we treated MRP2 
199 membrane vesicles in the above assay with equal amounts (33.3 µM) of various MC congeners- MC-LF, MC-
200 LR and MC-RR and assessed the inhibition of CDCF transport (Figure 4). CDCF transport activity was 
201 significantly decreased for MC-LF compared to the more hydrophilic MC-LR and MC-RR, thus suggesting a 
202 higher affinity for MC-LF than for MC-LR or -RR. The latter finding concurs with similar MC congener 
203 preferences reported for OATP-mediated cellular uptake [7]. 
204 Figure 4. MC-LF is transported more efficiently than MC-LR and MC-RR. 33.3 µM MC-LR, MC-RR or 
205 MC-LF were added to MRP2-membrane vesicles and competitive CDCF transport was determined after 30 
206 min. 100% CDCF transport is achieved in presence of solvent only. The absolute RFU value for 100% CDCF 
207 transport: 37902 ± 1725. Shown are n= 3 true replicates, mean ± SEM. p<0.05; ANOVA with Bonferroni 
208 correction and an additional t-test was used for pairwise comparisons.
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Figure 5. Efflux transporters: BCRP, BSEP, MRP1, MRP3, MRP5, and MDR1 do not transport MC-
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LR. Neither BCRP, BSEP, MRP1, MRP3, MRP5 or MDR1 presented with an appreciable MC-LR transport 
(left panel), despite that principally functional transport was demonstrated using the respective transporter 
inhibitors (right panel). % Transport was calculated with vehicle control (methanol or DMSO) resulting in 100% 
Fluorescent/radioactive substrate transport. The absolute RFU value for 100% Lucifer Yellow transport 
(BCRP): 30781 ± 1588, Taurine-2-3H transport in CPM (BSEP): 29332 ± 435, B-GS transport (MRP1): 25947 
± 1465, CDCF transport (MRP3): 28844 ± 1483, CDCF transport (MRP5): 31126 ±6801, 3H-NMQ transport 
in CPM (MDR1): 2071 ± 389. Shown are n= 3 true replicates, mean ± SEM.
209 In addition, we tested whether other human ABC-transporters - BCRP, BSEP, MRP1, MRP3, MRP5 and 
210 MDR1 show transport of MC-LR in membrane vesicles (Figure 5). While use of the respective transporter’s 
211 inhibitors demonstrated the functionality of the expressed transporter assays (Figure 5 right panel), exposure to 
212 MC-LR did not result in a concentration dependent reduction of reporter substrates (Figure 5 left panel), thereby 
213 suggesting that these transporters are not involved in MC-LR transport. Control membranes (without 
214 transporter) treated with MC-LR were used as control for transport specificity and showed no MC-LR transport 
215 in the absence of the corresponding transporter (Suppl. Fig 1). MRP4 could not be tested due to vesicle leakage 
216 and lack of significant differences between signal and background noise. Control membranes, lacking 
217 expression of MRP4 did not demonstrate increased reporter substrate or MC-LR levels thereby precluding 
218 presence of passive diffusion of either of the compounds (data not shown).
219 MCs were suggested to be exported from hepatocytes as conjugates (GSH and CYS) in rodents [32] as 
220 well as fish [19] although the transporter involved in their efflux is currently not established [33]. In order to 
221 test whether MRP2 transports the MC-LR glutathione conjugate (MC-LR-GSH), MC-LR-GSH was synthetized 
222 by reacting MC-LR with an excess of glutathione under basic conditions and purification of the conjugate by 
223 HPLC [34, 35]. As shown in Figure 6, transport of MC-LR-GSH by MRP2 is not suggested, at least under the 
224 conditions of the current setting. Due to limitations of available insect membrane vesicles containing the other 
225 exporters, we were unable to test whether any of the other transporters could be involved in the export of MC-
226 LR-GSH.
227 Figure 6. MRP2 does not transport MC-LR-GSH. Competitive CDCF transport was calculated after 
228 exposure of MRP2 membrane vesicles to different MC-LR-GSH concentrations (0-300 µM). % Transport was 
229 calculated with vehicle control (water) resulting in 100% Fluorescent substrate transport. The RFU for 100% 
230 CDCF transport were 13272 ± 1823. Shown are n= 3 true replicates, mean ± SEM.
231 Discussion
12 of 18
232 Microcystins taken up into hepatocytes via OATP1B1 and -1B3 are rapidly interacting with intracellular 
233 thiol containing peptides, polypeptides and macromolecules. The reversible and covalent interaction [16] with 
234 the catalytic subunit of Ser/Thr protein phosphatases (PPPs) [14] occurs in competition with glutathione 
235 conjugation [32] and the efflux from hepatocytes either as unchanged parent compound or as the glutathione 
236 conjugate. Although PPP inhibition, and thus the onset of cytotoxicity, is predominated by the interaction of 
237 unchanged parent MC, it was reported that glutathione conjugates as well as MC-cysteine conjugates, resulting 
238 from metabolism via -glutamyl transpeptidase and membrane bound dipeptidase [36], can also be toxic, albeit 
239 much higher concentrations are required for a similar degree of inhibition achieved with the parent MC-LR or 
240 MC-YR [37]. As “toxicity” is primarily the result of PPP inhibition, it can be safely assumed that the observed 
241 MC-cysteine and MC-glutathione conjugate toxicity in i.v. exposed mice, is a function of their inherent PPP 
242 inhibition capability. Although it remains to be demonstrated how either of the MC-cysteine or the MC-
243 glutathione conjugates would fit within the hydrophobic groove of the PPP catalytic subunit [38], the current 
244 toxicity data do suggest that glutathione conjugation is not entirely a detoxification reaction and thus is not 
245 sufficiently protective. Moreover, analytical assessment of MC metabolites murine, rat and porcine livers 
246 suggest that MC-glutathione conjugates can be further metabolized to MC-cysteine conjugates within the liver 
247 [15, 37, 39]. The latter emphasizes the importance of hepatocyte efflux transporters in reducing the cellular load 
248 of MC parent compound and metabolites.
249 It was surprising, however, that of the efflux transporters tested with the insect cell membrane vesicle 
250 assay (Figure 5), only MRP2 demonstrated appreciable MC-congener transport (Figures 2 and 3). Moreover, 
251 and contrary to our expectations, MRP2 did not transport the corresponding MC-LR-glutathione conjugate 
252 (Figure 6), indicating that other transporters are responsible for the efflux of MC-cysteine or the MC-glutathione 
253 conjugates from hepatocytes into the bile [19, 24, 25, 39] or possibly even back into the sinusoidal blood [40]. 
254 Some of the potential glutathione-conjugate transporters that indeed could transport MC-glutathione conjugates 
255 back into the sinusoidal blood would be MRPs 1,3, 4, and 6 (Figure 1). However only additional experiments 
256 using glutathione conjugates of a number of MC congeners and different ABC-transporter expressing systems, 
257 would allow better judgment of the situation. As MC-congener transport by MRP2 demonstrated similar MC-
258 congener dependency as we have previously demonstrated for the OATP uptake transporters [7], the question 
259 remains as to whether MC influx (OATP) and efflux (MRP2) rates compare. Indeed, we have established that 
260 for MC-LR influx via OATP1A2, 1B1 and 1B3 expressed in Xenopus oocytes, the vmax were 6, 3 and 11 
261 fmol/oocyte·min, while the km values were 20±8, 7±3, and 9±3 µM, thereby demonstrating dramatically 
262 differing capacities despite similar km values [12]. Indeed, OATP1B1 and 1B3 appeared to have nearly double 
263 the affinity for MC-LR than OATP1A2, while the capacity for transporting MC-LR of OATP1A2 remained 
264 somewhere between OATP1B1 and 1B3. Although difficult to compare, as we didn’t employ Xenopus oocytes 
265 as the transport testing system as was used for the OATPs, the approximated vmax and km values obtained for 
266 MRP2 in insect membrane vesicles were 235 nM/mg·min and 21 µM, thus suggesting that the affinity for MC-
267 LR of MRP2 is comparable to that of MC-LR to OATP1B1 and 1B3. In view of the fact that it was unclear how 
268 much OATP was expressed in the Xenopus oocyte system and how much MRP2 was present in the insect 
269 membrane vesicles, the hugely different transport capacity may be misleading. Irrespective of the latter the 
270 results we present here strongly suggest that MRP2 is a low affinity high capacity transporter for MC congeners 
271 albeit not of their glutathione conjugates. As most bile analyses for MCs and their conjugates were carried out 
272 via functional (PPP inhibition) but not via analytical (LC-MS/MS) means [19], it may well be that only the MC 
273 congener parent compound but not the glutathione or cysteine conjugates are excreted into the bile, whereas the 
274 glutathione or cysteine conjugate are excreted back into the sinusoidal blood. Although at present the latter is 
275 but a mere hypothesis, positive proof would have major implications on the evaluation of MC congener kinetics 
276 in humans and thus human risk assessment of MCs.
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388  Supplementary Materials: 
389 Supplementary Figure 1. Membrane vesicles without efflux transporters: BCRP, BSEP, MRP1, MRP3, 
390 MRP5, and MDR1 do not transport MC-LR. Control experiments with membrane vesicles lacking efflux 
391 transporters (BCRP (1A), BSEP (1B), MRP1 (1C), MRP3 (1D), MRP5 (1E) and MDR1 (1F)) did not show 
392 MC-LR transport. % Transport was calculated with vehicle control (methanol or DMSO) resulting in 100% 
393 Fluorescent/radioactive substrate transport. For 100% Lucifer Yellow transport (BCRP) amounted to 30781 ± 
394 1588 RFU. For taurine-2-3H (BSEP) 100% transport amounted to 29332 ± 435 CPM, For B-GS transport 
18 of 18
395 (MRP1) 100% transport amounted 25947 ± 1465 CPM. For CDCF transport (MRP3 and MRP5), 100% 
396 transport amounted to 28844 ± 1483 RFU and 31126 ±6801 RFU. For 3H-NMQ transport (MDR1) 100% 
397 transport amounted to 2071 ± 389 CPM. Shown are n= 3 true replicates, mean ± SEM.
398 Supplementary Figure 2. LC-MS chromatogram (254 nm) of MC-LR-GSH conjugate after HPLC 
399 purification showing a single product peak (Rt= 7.2 min).
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